ZYUS Life Sciences Activates First Clinical Site and Enrolls First Patient in Phase 2a UTOPIA-1 Cancer Pain Trial

Core Insights - ZYUS Life Sciences Corporation has initiated its Phase 2a UTOPIA-1 clinical trial to evaluate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules for patients with advanced cancer and moderate to severe cancer-related pain [1][2][4] Group 1: Clinical Trial Details - The UTOPIA-1 trial is a single-arm, proof-of-concept study focused on patients suffering from advanced cancer and significant pain [2] - The Centre Hospitalier de l'Université de Montréal (CHUM) has been activated as the first clinical site, with the first patient already enrolled and ongoing recruitment for additional patients [3][4] Group 2: Company Objectives and Commitment - The activation of the first site and patient enrollment is seen as a significant advancement in ZYUS' clinical development program, highlighting the company's commitment to providing non-opioid pain management solutions [3][4] - ZYUS aims to bridge the treatment gap between conventional therapies like opioids and NSAIDs, offering a differentiated, evidence-based approach for managing cancer pain [4] Group 3: Company Overview - ZYUS Life Sciences Corporation is focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management, with an emphasis on securing intellectual property and obtaining regulatory approval [5] - The company is dedicated to making a transformational impact on patients' lives through innovative therapies [5]